ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v22i2.2884ppharm-2600Research ArticleКЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИCLINICAL RECOMMENDATIONSПроект клинических рекомендаций по диагностике и лечению метаболически ассоциированной жировой болезни печени у детей (неалкогольной жировой болезни печени)Draft Clinical Guidelines for the Diagnosis and Treatment of Metabolically Associated Fatty Liver Disease in Children (Non-Alcoholic Fatty Liver Disease)https://orcid.org/0000-0003-3987-8112БарановА. А.BaranovAlexander A.

Москва

Moscow

https://orcid.org/0000-0002-5413-9599ВолынецГ. В.VolynetsGalina V.

Москва

Moscow

https://orcid.org/0009-0005-7665-4793ВласовН. Н.VlasovNikolay N.

Санкт-Петербург

St. Petersburg

https://orcid.org/0000-0001-7890-733XГорячеваЛ. Г.GoryachevaLarisa G.

Санкт-Петербург

St. Petersburg

https://orcid.org/0000-0002-2666-4759ГуроваМ. М.GurovaMargarita M.

Санкт-Петербург

St. Petersburg

https://orcid.org/0000-0002-4509-5352ГрешняковаВ. А.GreshnyakovaVera A.

Санкт-Петербург

St. Petersburg

https://orcid.org/0000-0002-9532-9698ЗавьяловаА. Н.ZaviyalovaAnna N.

Санкт-Петербург

St. Petersburg

ЕвдокимоваН. В.EvdokimovaNina V.

Санкт-Петербург

St. Petersburg

https://orcid.org/0000-0002-1533-4498КомиссароваМ. Ю.KomissarovaMarina Yu.

Красногорск

Krasnogorsk

https://orcid.org/0000-0002-2209-7531Намазова-БарановаЛ. С.Namazova-BaranovaLeyla S.

Намазова-Баранова Лейла Сеймуровна - доктор медицинских наук, профессор, академик РАН, заведующая кафедрой факультетской педиатрии Института материнства и детства ФГАОУ ВО РНИМУ им. Н.И. Пирогова (Пироговский Университет), руководитель НИИ педиатрии и охраны здоровья детей НКЦ №2 ФГБНУ «РНЦХ им. акад. Б.В. Петровского», президент Союза педиатров России.

119333, Москва, ул. Фотиевой, д. 10, тел.: +7 (499) 400-47-33

Moscow

lsnamazova@yandex.ruhttps://orcid.org/0000-0002-0992-1709НовиковаВ. П.NovikovaValeriya P.

Санкт-Петербург

St. Petersburg

https://orcid.org/0000-0002-4505-397XПавловскаяЕ. В.PavlovskayaElena V.

Москва

Moscow

https://orcid.org/0000-0003-0968-6291РогозинаН. В.RogozinaNatalya V.

Санкт-Петербург

St. Petersburg

https://orcid.org/0000-0002-0762-0873СтроковаТ. В.StrokovaTatiana V.

Москва

Moscow

https://orcid.org/0000-0002-3697-4283СурковА. Н.SurkovAndrey N.

Москва

Moscow

https://orcid.org/0000-0001-7308-7280ХавкинА. И.HavkinAnatoly I.

Москва, Белгород

Moscow, Belgorod

НИИ педиатрии и охраны здоровья детей НКЦ №2 ФГБНУ «РНЦХ им. акад. Б.В. Петровского»; Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет)РоссияResearch Institute of Pediatrics and Children’s Health in Petrovsky National Research Centre of Surgery; Sechenov Moscow Medical AcademyRussian FederationНаучно-исследовательский клинический институт педиатрии и детской хирургии им. акад. Ю.Е. Вельтищева; Российский национальный исследовательский медицинский университет им. Н.И. Пирогова (Пироговский Университет)РоссияVeltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery; Pirogov Russian National Research Medical UniversityRussian FederationСанкт-Петербургский государственный педиатрический медицинский университетРоссияSaint Petersburg State Pediatric Medical UniversityRussian FederationСанкт-Петербургский государственный педиатрический медицинский университет; Детский научно-клинический центр инфекционных болезнейРоссияSaint Petersburg State Pediatric Medical University; Pediatric Research and Clinical Center for Infectious DiseasesRussian FederationДетский научно-клинический центр инфекционных болезнейРоссияPediatric Research and Clinical Center for Infectious DiseasesRussian FederationДетский клинический центр им. Л.М. РошаляРоссияRoshal Children’s Clinical CentreRussian FederationНИИ педиатрии и охраны здоровья детей НКЦ №2 ФГБНУ «РНЦХ им. акад. Б.В. Петровского»; Российский национальный исследовательский медицинский университет им. Н.И. Пирогова (Пироговский Университет)РоссияResearch Institute of Pediatrics and Children’s Health in Petrovsky National Research Centre of Surgery; Pirogov Russian National Research Medical UniversityRussian FederationФедеральный исследовательский центр питания, биотехнологии и безопасности пищи; Российская медицинская академия непрерывного профессионального образованияРоссияScientific Research Institute of Nutrition; Russian Medical Academy of Continuing Professional EducationRussian FederationРоссийский национальный исследовательский медицинский университет им. Н.И. Пирогова (Пироговский Университет); Федеральный исследовательский центр питания, биотехнологии и безопасности пищиРоссияPirogov Russian National Research Medical University; Scientific Research Institute of NutritionRussian FederationНаучно-исследовательский клинический институт детства; Белгородский государственный национальный исследовательский университетРоссияResearch and Clinical Institute for Children; Belgorod State UniversityRussian Federation202523052025222147163Copyright © Баранов А.А., Волынец Г.В., Власов Н.Н., Горячева Л.Г., Гурова М.М., Грешнякова В.А., Завьялова А.Н., Евдокимова Н.В., Комиссарова М.Ю., Намазова-Баранова Л.С., Новикова В.П., Павловская Е.В., Рогозина Н.В., Строкова Т.В., Сурков А.Н., Хавкин А.И., 20252025Баранов А.А., Волынец Г.В., Власов Н.Н., Горячева Л.Г., Гурова М.М., Грешнякова В.А., Завьялова А.Н., Евдокимова Н.В., Комиссарова М.Ю., Намазова-Баранова Л.С., Новикова В.П., Павловская Е.В., Рогозина Н.В., Строкова Т.В., Сурков А.Н., Хавкин А.И.Baranov A.A., Volynets G.V., Vlasov N.N., Goryacheva L.G., Gurova M.M., Greshnyakova V.A., Zaviyalova A.N., Evdokimova N.V., Komissarova M.Y., Namazova-Baranova L.S., Novikova V.P., Pavlovskaya E.V., Rogozina N.V., Strokova T.V., Surkov A.N., Havkin A.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/2600

Авторами представлены современные эпидемиологические данные и особенности этиопатогенеза метаболически ассоциированной жировой болезни печени у детей (неалкогольной жировой болезни печени), даны клинические характеристики различных вариантов данной нозологии. Приведены сведения по лабораторно-инструментальным и морфологическим признакам метаболически ассоциированной жировой болезни печени у детей, а также о методах профилактики, лечения и реабилитации в соответствии с разработанными клиническими рекомендациями.

The authors present modern epidemiological data and features of the etiopathogenesis of metabolically associated fatty liver disease in children (non-alcoholic fatty liver disease), and provide clinical characteristics of various variants of this nosology. Information is provided on laboratory, instrumental and morphological signs of metabolically associated fatty liver disease in children, as well as on methods of prevention, treatment and rehabilitation in accordance with developed clinical guidelines.

метаболически ассоциированная жировая болезнь печени (неалкогольная жировая болезнь печени)клинические рекомендациидетиmetabolic-associated fatty liver disease (non-alcoholic fatty liver disease)clinical guidelineschildrenОтсутствуетNot specifiedReferencesVos MV, Abrams SH, Barlow SE, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the expert committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr. 2017;64(2):319–334. doi: https://doi.org/10.1097/MPG.0000000000001482Vos MV, Abrams SH, Barlow SE, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the expert committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr. 2017;64(2):319–334. doi: https://doi.org/10.1097/MPG.0000000000001482Ten Hove M, Pater L, Storm G, et al. The hepatic lipidome: From basic science to clinical translation. Adv Drug Deliv Rev. 2020; 159:180–197. doi: https://doi.org/10.1016/j.addr.2020.06.027Ten Hove M, Pater L, Storm G, et al. The hepatic lipidome: From basic science to clinical translation. Adv Drug Deliv Rev. 2020; 159:180–197. doi: https://doi.org/10.1016/j.addr.2020.06.027Abdelmalek MF. Nonalcoholic fatty liver disease: another leap forward. Nat Rev Gastroenterol Hepatol. 2021;18(2):85–86. doi: https://doi.org/10.1038/s41575-020-00406-0Abdelmalek MF. Nonalcoholic fatty liver disease: another leap forward. Nat Rev Gastroenterol Hepatol. 2021;18(2):85–86. doi: https://doi.org/10.1038/s41575-020-00406-0Cotter TG, Rinella M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology. 2020;158(7):1851–1864. doi: https://doi.org/10.1053/j.gastro.2020.01.052Cotter TG, Rinella M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology. 2020;158(7):1851–1864. doi: https://doi.org/10.1053/j.gastro.2020.01.052Crane H, Gofton C, Sharma A, George J. MAFLD: an optimal framework for understanding liver cancer phenotypes. J Gastroenterol. 2023;58(10):947–964. doi: https://doi.org/10.1007/s00535-02302021-7Crane H, Gofton C, Sharma A, George J. MAFLD: an optimal framework for understanding liver cancer phenotypes. J Gastroenterol. 2023;58(10):947–964. doi: https://doi.org/10.1007/s00535-02302021-7Gofton C, Upendran Y, Zheng MH, George J. MAFLD: How is it different from NAFLD? Clin Mol Hepatol. 2023;29(Suppl):S17–S31. doi: https://doi.org/10.3350/cmh.2022.0367Gofton C, Upendran Y, Zheng MH, George J. MAFLD: How is it different from NAFLD? Clin Mol Hepatol. 2023;29(Suppl):S17–S31. doi: https://doi.org/10.3350/cmh.2022.0367Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci. 2019 Jan;76(1):99–128. doi: https://doi.org/10.1007/s00018-018-2947-0Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci. 2019 Jan;76(1):99–128. doi: https://doi.org/10.1007/s00018-018-2947-0Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643–654.e1–e9; quiz e39–40. doi: https://doi.org/10.1016/j.cgh.2014.04.014Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643–654.e1–e9; quiz e39–40. doi: https://doi.org/10.1016/j.cgh.2014.04.014Eslam M, Alkhouri N, Vajro P, et al. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol. 2021;6(10):864– 873. doi: https://doi.org/10.1016/S2468-1253(21)00183-7Eslam M, Alkhouri N, Vajro P, et al. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol. 2021;6(10):864– 873. doi: https://doi.org/10.1016/S2468-1253(21)00183-7Colucci A, Chaira Rocco M, De Anseris A, et al. Pediatric vs. adult NAFLD to MAFLD transition: a welcome but tangled path. Explor Med. 2021;2(4):333–342.Colucci A, Chaira Rocco M, De Anseris A, et al. Pediatric vs. adult NAFLD to MAFLD transition: a welcome but tangled path. Explor Med. 2021;2(4):333–342.Le Garf S, Nègre V, Anty R, Gual P. Metabolic fatty liver disease in children: a growing public health problem. Biomedicines. 2021;9(12):1915. doi: https://doi.org/10.3390/biomedicines9121915Le Garf S, Nègre V, Anty R, Gual P. Metabolic fatty liver disease in children: a growing public health problem. Biomedicines. 2021;9(12):1915. doi: https://doi.org/10.3390/biomedicines9121915Hegarty R, Kyrana E, Fitzpatrick E, Dhawan A. Fatty liver disease in children (MAFLD/PeFLD Type 2): unique classification considerations and challenges. Ther Adv Endocrinol Metab. 2023;14:20420188231160388. doi: https://doi.org/10.1177/20420188231160388Hegarty R, Kyrana E, Fitzpatrick E, Dhawan A. Fatty liver disease in children (MAFLD/PeFLD Type 2): unique classification considerations and challenges. Ther Adv Endocrinol Metab. 2023;14:20420188231160388. doi: https://doi.org/10.1177/20420188231160388Zhang L, El-Shabrawi M, Baur LA, et al. An international multidisciplinary consensus on pediatric metabolic dysfunctionassociated fatty liver disease. Med. 2024;7(5):797–815. doi: https://doi.org/10.1016/j.medj.2024.03.017Zhang L, El-Shabrawi M, Baur LA, et al. An international multidisciplinary consensus on pediatric metabolic dysfunctionassociated fatty liver disease. Med. 2024;7(5):797–815. doi: https://doi.org/10.1016/j.medj.2024.03.017Haas JT, Francque S, Staels B. Pathophysiology and mechanisms of nonalcoholic fatty liver disease. Annu Rev Physiol. 2016;78:181–205. doi: https://doi.org/10.1146/annurev-physiol-021115-105331Haas JT, Francque S, Staels B. Pathophysiology and mechanisms of nonalcoholic fatty liver disease. Annu Rev Physiol. 2016;78:181–205. doi: https://doi.org/10.1146/annurev-physiol-021115-105331Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018;75(18):3313–3327. doi: https://doi.org/10.1007/s00018-018-2860-6Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018;75(18):3313–3327. doi: https://doi.org/10.1007/s00018-018-2860-6Antonella M, Pietrobattista A, Maggiore G. Metabolic-Associated Steatotic Liver Disease (MASLD): A New Term for a More Appropriate Therapy in Pediatrics? Pediatr Rep. 2024;16(2):288–299. doi: https://doi.org/10.3390/pediatric16020025Antonella M, Pietrobattista A, Maggiore G. Metabolic-Associated Steatotic Liver Disease (MASLD): A New Term for a More Appropriate Therapy in Pediatrics? Pediatr Rep. 2024;16(2):288–299. doi: https://doi.org/10.3390/pediatric16020025EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388– 1402. doi: https://doi.org/10.1016/j.jhep.2015.11.004EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388– 1402. doi: https://doi.org/10.1016/j.jhep.2015.11.004Eslam M, Sanyal AJ, George J, et al. International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999– 2014.e1. doi: https://doi.org/10.1053/j.gastro.2019.11.312Eslam M, Sanyal AJ, George J, et al. International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999– 2014.e1. doi: https://doi.org/10.1053/j.gastro.2019.11.312Vittorio J, Lavine JE. Recent advances in understanding and managing pediatric nonalcoholic fatty liver disease. F1000Res. 2020;9:F1000 Faculty Rev-377. doi: https://doi.org/10.12688/f1000research.24198.1Vittorio J, Lavine JE. Recent advances in understanding and managing pediatric nonalcoholic fatty liver disease. F1000Res. 2020;9:F1000 Faculty Rev-377. doi: https://doi.org/10.12688/f1000research.24198.1Schwimmer JB, Deutsch R, Kahen T, et al. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006;118(4):1388– 1393. doi: https://doi.org/10.1542/peds.2006-1212Schwimmer JB, Deutsch R, Kahen T, et al. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006;118(4):1388– 1393. doi: https://doi.org/10.1542/peds.2006-1212Byrne CD, Targher G. NAFLD: A multisystem disease. J Hepatol. 2015;62(1 Suppl):S47–S64. doi: https://doi.org/10.1016/j.jhep.2014.12.012Byrne CD, Targher G. NAFLD: A multisystem disease. J Hepatol. 2015;62(1 Suppl):S47–S64. doi: https://doi.org/10.1016/j.jhep.2014.12.012Zhao Y, Wang SZ, Zhao YB, et al. Mitochondrial dysfunction in metabolic dysfunction fatty liver disease (MAFLD). Int J Mol Sci. 2023;24(24):17514. doi: https://doi.org/10.3390/ijms242417514Zhao Y, Wang SZ, Zhao YB, et al. Mitochondrial dysfunction in metabolic dysfunction fatty liver disease (MAFLD). Int J Mol Sci. 2023;24(24):17514. doi: https://doi.org/10.3390/ijms242417514Branković M, Dukić M, Gmizić T, et al. New Therapeutic approaches for the treatment of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and increased cardiovascular risk. Diagnostics (Basel). 2024;14(2):229. doi: https://doi.org/10.3390/diagnostics14020229Branković M, Dukić M, Gmizić T, et al. New Therapeutic approaches for the treatment of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and increased cardiovascular risk. Diagnostics (Basel). 2024;14(2):229. doi: https://doi.org/10.3390/diagnostics14020229Boney CM, Verma A, Tucker R, Vohr BR. Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics. 2005;115(3):e290–e296. doi: https://doi.org/10.1542/peds.2004-1808Boney CM, Verma A, Tucker R, Vohr BR. Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics. 2005;115(3):e290–e296. doi: https://doi.org/10.1542/peds.2004-1808DeVore S, Kohli R, Lake K, et al. A multidisciplinary clinical program is effective in stabilizing BMI and reducing transaminase levels in pediatric patients with NAFLD. J Pediatr Gastroenterol Nutr. 2013;57(1):119–123. doi: https://doi.org/10.1097/MPG.0b013e318290d138DeVore S, Kohli R, Lake K, et al. A multidisciplinary clinical program is effective in stabilizing BMI and reducing transaminase levels in pediatric patients with NAFLD. J Pediatr Gastroenterol Nutr. 2013;57(1):119–123. doi: https://doi.org/10.1097/MPG.0b013e318290d138Alfani R, Vassallo E, De Anseris AG, et al. Pediatric fatty liver and obesity: not always just a matter of non-alcoholic fatty liver disease. Children (Basel). 2018;5(12):169. doi: https://doi.org/10.3390/children5120169Alfani R, Vassallo E, De Anseris AG, et al. Pediatric fatty liver and obesity: not always just a matter of non-alcoholic fatty liver disease. Children (Basel). 2018;5(12):169. doi: https://doi.org/10.3390/children5120169Vimalesvaran S, Vajro P, Dhawan A. Pediatric metabolic (dysfunction)-associated fatty liver disease: current insights and future perspectives. Hepatol Int. 2024;18(Suppl 2):873–883. doi: https://doi.org/10.1007/s12072-024-10691-5Vimalesvaran S, Vajro P, Dhawan A. Pediatric metabolic (dysfunction)-associated fatty liver disease: current insights and future perspectives. Hepatol Int. 2024;18(Suppl 2):873–883. doi: https://doi.org/10.1007/s12072-024-10691-5Петеркова В.А., Нагаева Е.В., Ширяева Т.Ю. Оценка физического развития детей и подростков: методические рекомендации. — М.; 2017. — 98 с.Peterkova VA, Nagaeva EV, Shiryaeva TYu. Otsenka fizicheskogo razvitiya detei i podrostkov: Methodological recommendations. Moscow; 2017. 98 p. (In Russ).Маевская М.В. Котовская Ю.В., Ивашкин В.Т. и др. Национальный Консенсус для врачей по ведению взрослых пациентов с неалкогольной жировой болезнью печени и ее основными коморбидными состояниями // Терапевтический архив. — 2022. — Т. 94. — № 2. — C. 216–253. — doi: https://doi.org/10.26442/00403660.2022.02.201363Maevskaya MV, Kotovskaya YuV, Ivashkin VT, et al. The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. Terapevticheskii Arkhiv. 2022;94(2):216–253. (In Russ). doi: https://doi.org/10.26442/00403660.2022.02.201363Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res. 2012;2012:145754. doi: https://doi.org/10.1155/2012/145754Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res. 2012;2012:145754. doi: https://doi.org/10.1155/2012/145754Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–1986. doi: https://doi.org/10.1097/HEP.0000000000000520Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–1986. https://doi.org/10.1097/HEP.0000000000000520Draijer LG, Feddouli S, Bohte AE, et al. Comparison of diagnostic accuracy of screening tests ALT and ultrasound for pediatric nonalcoholic fatty liver disease. Eur J Pediatr. 2019;178(6):863–870. doi: https://doi.org/10.1007/s00431-019-03362-3Draijer LG, Feddouli S, Bohte AE, et al. Comparison of diagnostic accuracy of screening tests ALT and ultrasound for pediatric nonalcoholic fatty liver disease. Eur J Pediatr. 2019;178(6):863–870. doi: https://doi.org/10.1007/s00431-019-03362-3Draijer L, Benninga M, Koot B. Pediatric NAFLD: an overview and recent developments in diagnostics and treatment. Expert Rev Gastroenterol Hepatol. 2019;13(5):447–461. doi: https://doi.org/10.1080/17474124.2019.1595589Draijer L, Benninga M, Koot B. Pediatric NAFLD: an overview and recent developments in diagnostics and treatment. Expert Rev Gastroenterol Hepatol. 2019;13(5):447–461. doi: https://doi.org/10.1080/17474124.2019.1595589Ferraioli G, Soares Monteiro LB. Ultrasound-based techniques for the diagnosis of liver steatosis. World J Gastroenterol. 2019;25(40):6053–6062. doi: https://doi.org/10.3748/wjg.v25.i40.6053Ferraioli G, Soares Monteiro LB. Ultrasound-based techniques for the diagnosis of liver steatosis. World J Gastroenterol. 2019;25(40):6053–6062. doi: https://doi.org/10.3748/wjg.v25.i40.6053Ferraioli G, Calcaterra V, Lissandrin R, et al. Noninvasive assessment of liver steatosis in children: the clinical value of controlled attenuation parameter. BMC Gastroenterol. 2017;17(1):61. doi: https://doi.org/10.1186/s12876-017-0617-6Ferraioli G, Calcaterra V, Lissandrin R, et al. Noninvasive assessment of liver steatosis in children: the clinical value of controlled attenuation parameter. BMC Gastroenterol. 2017;17(1):61. doi: https://doi.org/10.1186/s12876-017-0617-6Pu K, Wang Y, Bai S, et al. Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis. BMC gastroenterol. 2019;19(1):51. doi: https://doi.org/10.1186/s12876-019-0961-9Pu K, Wang Y, Bai S, et al. Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis. BMC gastroenterol. 2019;19(1):51. doi: https://doi.org/10.1186/s12876-019-0961-9Shin J, Kim MJ, Shin HJ, et al. Quick assessment with controlled attenuation parameter for hepatic steatosis in children based on MRI-PDFF as the gold standard. BMC Pediatr. 2019;19(1):112. doi: https://doi.org/10.1186/s12887-019-1485-8Shin J, Kim MJ, Shin HJ, et al. Quick assessment with controlled attenuation parameter for hepatic steatosis in children based on MRI-PDFF as the gold standard. BMC Pediatr. 2019;19(1):112. doi: https://doi.org/10.1186/s12887-019-1485-8Schwimmer JB, Middleton MS, Behling C, et al. Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease. Hepatology. 2015;69(6):1887–1895. doi: https://doi.org/10.1002/hep.27666Schwimmer JB, Middleton MS, Behling C, et al. Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease. Hepatology. 2015;69(6):1887–1895. https://doi.org/10.1002/hep.27666Verhaegh P, Bavalia R, Winkens B, et al. Noninvasive tests do not accurately differentiate nonalcoholic steatohepatitis from simple steatosis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16(6):837–861. doi: https://doi.org/10.1016/j.cgh.2017.08.024Verhaegh P, Bavalia R, Winkens B, et al. Noninvasive tests do not accurately differentiate nonalcoholic steatohepatitis from simple steatosis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16(6):837–861. doi: https://doi.org/10.1016/j.cgh.2017.08.024Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–1321. doi: https://doi.org/10.1002/hep.20701Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–1321. doi: https://doi.org/10.1002/hep.20701Nobili V, Alisi A, Newton KP, Schwimmer JB. Comparison of the phenotype and approach to pediatric vs adult patients with nonalcoholic fatty liver disease. Gastroenterology. 2016;150(8):1798–1810. doi: https://doi.org/10.1053/j.gastro.2016.03.009Nobili V, Alisi A, Newton KP, Schwimmer JB. Comparison of the phenotype and approach to pediatric vs adult patients with nonalcoholic fatty liver disease. Gastroenterology. 2016;150(8):1798–1810. doi: https://doi.org/10.1053/j.gastro.2016.03.009Papatheodoridi M, Hiriart JB, Lupsor-Platon M, et al. Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. J Hepatol. 2021;74(5):1109–1116. doi: https://doi.org/10.1016/j.jhep.2020.11.050Papatheodoridi M, Hiriart JB, Lupsor-Platon M, et al. Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. J Hepatol. 2021;74(5):1109–1116. doi: https://doi.org/10.1016/j.jhep.2020.11.050Petroff D, Blank V, Newsome PN, et al. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(3):185–198. doi: https://doi.org/10.1016/S2468-1253(20)30357-5Petroff D, Blank V, Newsome PN, et al. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(3):185–198. doi: https://doi.org/10.1016/S2468-1253(20)30357-5Chen BR, Pan CQ. Non-invasive assessment of fibrosis and steatosis in pediatric non-alcoholic fatty liver disease. Clin Res Hepatol Gastroenterol. 2022;46(1):101755. doi: https://doi.org/10.1016/j.clinre.2021.101755Chen BR, Pan CQ. Non-invasive assessment of fibrosis and steatosis in pediatric non-alcoholic fatty liver disease. Clin Res Hepatol Gastroenterol. 2022;46(1):101755. doi: https://doi.org/10.1016/j.clinre.2021.101755Nobili V, Alisi A, Vania A, et al. The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease. BMC Med. 2009;7:21. doi: https://doi.org/10.1186/17417015-7-21Nobili V, Alisi A, Vania A, et al. The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease. BMC Med. 2009;7:21. doi: https://doi.org/10.1186/17417015-7-21Yang HR, Kim HR, Kim MJ, et al. Noninvasive parameters and hepatic fibrosis scores in children with nonalcoholic fatty liver disease. World J Gastroenterol. 2012;18(13):1525–1530. doi: https://doi.org/10.3748/wjg.v18.i13.1525Yang HR, Kim HR, Kim MJ, et al. Noninvasive parameters and hepatic fibrosis scores in children with nonalcoholic fatty liver disease. World J Gastroenterol. 2012;18(13):1525–1530. doi: https://doi.org/10.3748/wjg.v18.i13.1525Lin YC, Wu CC, Ni YH. New perspectives on genetic prediction for pediatric metabolic associated fatty liver disease. Front Pediatr. 2020;8:603654. doi: https://doi.org/10.3389/fped.2020.603654Lin YC, Wu CC, Ni YH. New perspectives on genetic prediction for pediatric metabolic associated fatty liver disease. Front Pediatr. 2020;8:603654. doi: https://doi.org/10.3389/fped.2020.603654González-Ruiz K, Ramírez-Vélez R, Correa-Bautista JE, et al. The Effects of Exercise on Abdominal Fat and Liver Enzymes in Pediatric Obesity: A Systematic Review and Meta-Analysis. Child Obes. 2017;13(4):272–282. doi: https://doi.org/10.1089/chi.2017.0027González-Ruiz K, Ramírez-Vélez R, Correa-Bautista JE, et al. The Effects of Exercise on Abdominal Fat and Liver Enzymes in Pediatric Obesity: A Systematic Review and Meta-Analysis. Child Obes. 2017;13(4):272–282. doi: https://doi.org/10.1089/chi.2017.0027Keating SE, Hackett DA, George J, Johnson NA. Exercise and nonalcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012;57(1):157–166. doi: https://doi.org/10.1016/j.jhep.2012.02.023Keating SE, Hackett DA, George J, Johnson NA. Exercise and nonalcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012;57(1):157–166. doi: https://doi.org/10.1016/j.jhep.2012.02.023Hashida R, Kawaguchi T, Bekki M, et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. J Hepatol. 2017;66(1):142–152. doi: https://doi.org/10.1016/j.jhep.2016.08.023Hashida R, Kawaguchi T, Bekki M, et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. J Hepatol. 2017;66(1):142–152. doi: https://doi.org/10.1016/j.jhep.2016.08.023WHO guidelines on physical activity and sedentary behaviour. Geneva: World Health Organization; 2020.WHO guidelines on physical activity and sedentary behaviour. Geneva: World Health Organization; 2020.Ramon-Krauel M, Salsberg SL, Ebbeling CB, et al. A lowglycemic-load versus low-fat diet in the treatment of fatty liver in obese children. Child Obes. 2013;9(3):252–260. doi: https://doi.org/10.1089/chi.2013.0022Ramon-Krauel M, Salsberg SL, Ebbeling CB, et al. A lowglycemic-load versus low-fat diet in the treatment of fatty liver in obese children. Child Obes. 2013;9(3):252–260. doi: https://doi.org/10.1089/chi.2013.0022Nobili V, Marcellini M, Devito R, et al. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology. 2006;44(2):458–465. doi: https://doi.org/10.1002/hep.21262Nobili V, Marcellini M, Devito R, et al. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology. 2006;44(2):458–465. doi: https://doi.org/10.1002/hep.21262de Ruyter JC, Olthof MR, Seidell JC, Katan M. A trial of sugar-free or sugar-sweetened beverages and body weight in children. N Engl J Med. 2012;367(15):1397–1406. doi: https://doi.org/10.1056/NEJMoa1203034de Ruyter JC, Olthof MR, Seidell JC, Katan M. A trial of sugar-free or sugar-sweetened beverages and body weight in children. N Engl J Med. 2012;367(15):1397–1406. doi: https://doi.org/10.1056/NEJMoa1203034Ebbeling CB, Feldman HA, Chomitz VR, et al. A randomized trial of sugar-sweetened beverages and adolescent body weight. N Engl J Med. 2012;367(15):1407–1416. doi: https://doi.org/10.1056/NEJMoa1203388Ebbeling CB, Feldman HA, Chomitz VR, et al. A randomized trial of sugar-sweetened beverages and adolescent body weight. N Engl J Med. 2012;367(15):1407–1416. doi: https://doi.org/10.1056/NEJMoa1203388Schwimmer JB, Ugalde-Nicalo P, Welsh JA, et al. Effect of a low free sugar diet vs usual diet on nonalcoholic fatty liver disease in adolescent boys: a randomized clinical trial. JAMA. 2019;321(3):256– 265. doi: https://doi.org/10.1001/jama.2018.20579Schwimmer JB, Ugalde-Nicalo P, Welsh JA, et al. Effect of a low free sugar diet vs usual diet on nonalcoholic fatty liver disease in adolescent boys: a randomized clinical trial. JAMA. 2019;321(3):256– 265. doi: https://doi.org/10.1001/jama.2018.20579Lee D, Chiavaroli L, Ayoub-Charette S, et al. Important food sources of fructose-containing sugars and non-alcoholic fatty liver disease: A systematic review and meta-analysis of controlled trials. Nutrients. 2022;14(14):2846. doi: https://doi.org/10.3390/nu14142846Lee D, Chiavaroli L, Ayoub-Charette S, et al. Important food sources of fructose-containing sugars and non-alcoholic fatty liver disease: A systematic review and meta-analysis of controlled trials. Nutrients. 2022;14(14):2846. doi: https://doi.org/10.3390/nu14142846Cohen CC, Li KW, Alazraki AL, et al. Dietary sugar restriction reduces hepatic de novo lipogenesis in adolescent boys with fatty liver disease. J Clin Invest. 2021;131(24):e150996. doi: https://doi.org/10.1172/JCI150996Cohen CC, Li KW, Alazraki AL, et al. Dietary sugar restriction reduces hepatic de novo lipogenesis in adolescent boys with fatty liver disease. J Clin Invest. 2021;131(24):e150996. doi: https://doi.org/10.1172/JCI150996Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829– 846. doi: https://doi.org/10.1016/j.jhep.2017.05.016Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829– 846. doi: https://doi.org/10.1016/j.jhep.2017.05.016Pacifico L, Bonci E, Di Martino M, et al. A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2015;25(8):734–741. doi: https://doi.org/10.1016/j.numecd.2015.04.003Pacifico L, Bonci E, Di Martino M, et al. A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2015;25(8):734–741. doi: https://doi.org/10.1016/j.numecd.2015.04.003Janczyk W, Lebensztejn D, Wierzbicka-Rucińska A, et al. Omega-3 fatty acids therapy in children with nonalcoholic fatty liver disease: a randomized controlled trial. J Pediatr. 2015;166(6):1358–1363. doi: https://doi.org/10.1016/j.jpeds.2015.01.056Janczyk W, Lebensztejn D, Wierzbicka-Rucińska A, et al. Omega-3 fatty acids therapy in children with nonalcoholic fatty liver disease: a randomized controlled trial. J Pediatr. 2015;166(6):1358–1363. doi: https://doi.org/10.1016/j.jpeds.2015.01.056Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305(16):1659–1668. doi: https://doi.org/10.1001/jama.2011.520Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305(16):1659–1668. doi: https://doi.org/10.1001/jama.2011.520Flisiak-Jackiewicz M, Lebensztejn DM. Update on pathogenesis, diagnostics and therapy of nonalcoholic fatty liver disease in children. Clin Exp Hepatol. 2019;5(1):11–21. doi: https://doi.org/10.5114/ceh.2019.83152Flisiak-Jackiewicz M, Lebensztejn DM. Update on pathogenesis, diagnostics and therapy of nonalcoholic fatty liver disease in children. Clin Exp Hepatol. 2019;5(1):11–21. doi: https://doi.org/10.5114/ceh.2019.83152Cheng FS, Pan D, Chang B, et al. Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases. World J Clin Cases. 2020;8(8):1361–1384. doi: https://doi.org/10.12998/wjcc.v8.i8.1361Cheng FS, Pan D, Chang B, et al. Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases. World J Clin Cases. 2020;8(8):1361–1384. doi: https://doi.org/10.12998/wjcc.v8.i8.1361Alisi A, Bedogni G, Baviera G, et al. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2014;39(11):1276–1285. doi: https://doi.org/10.1111/apt.12758Alisi A, Bedogni G, Baviera G, et al. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2014;39(11):1276–1285. doi: https://doi.org/10.1111/apt.12758Vajro P, Mandato C, Licenziati MR, et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr. 2011;52(6):740–743. doi: https://doi.org/10.1097/MPG.0b013e31821f9b85Vajro P, Mandato C, Licenziati MR, et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr. 2011;52(6):740–743. doi: https://doi.org/10.1097/MPG.0b013e31821f9b85Famouri F, Shariat Z, Hashemipour M, et al. Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents. J Pediatr Gastroenterol Nutr. 2017;64(3):413–417. doi: https://doi.org/10.1097/MPG.0000000000001422Famouri F, Shariat Z, Hashemipour M, et al. Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents. J Pediatr Gastroenterol Nutr. 2017;64(3):413–417. doi: https://doi.org/10.1097/MPG.0000000000001422Temple JL, Cordero P, Li J, et al. A Guide to nonalcoholic fatty liver disease in childhood and adolescence. Int J Mol Sci. 2016;17(6):947. doi: https://doi.org/10.3390/ijms17060947Temple JL, Cordero P, Li J, et al. A Guide to nonalcoholic fatty liver disease in childhood and adolescence. Int J Mol Sci. 2016;17(6):947. doi: https://doi.org/10.3390/ijms17060947Lin X, Mai M, He T, et al. Efficiency of ursodeoxycholic acid for the treatment of nonalcoholic steatohepatitis: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2022;16(6):537–545. doi: https://doi.org/10.1080/17474124.2022.2083605Lin X, Mai M, He T, et al. Efficiency of ursodeoxycholic acid for the treatment of nonalcoholic steatohepatitis: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2022;16(6):537–545. doi: https://doi.org/10.1080/17474124.2022.2083605Bjelakovic GI, Nikolova D, Gluud C. Meta-regression analyses, meta-analyses, and trial sequential analyses of the effects of supplementation with beta-carotene, vitamin A, and vitamin E singly or in different combinations on all-cause mortality: do we have evidence for lack of harm? PLoS One. 2013;8(9):e74558. doi: https://doi.org/10.1371/journal.pone.0074558Bjelakovic GI, Nikolova D, Gluud C. Meta-regression analyses, meta-analyses, and trial sequential analyses of the effects of supplementation with beta-carotene, vitamin A, and vitamin E singly or in different combinations on all-cause mortality: do we have evidence for lack of harm? PLoS One. 2013;8(9):e74558. doi: https://doi.org/10.1371/journal.pone.0074558Bjelakovic G, Nikolova D, Gluud LL, et al. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev. 2012;2012(3):CD007176. doi: https://doi.org/10.1002/14651858.CD007176.pub2Bjelakovic G, Nikolova D, Gluud LL, et al. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev. 2012;2012(3):CD007176. doi: https://doi.org/10.1002/14651858.CD007176.pub2Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679–690. doi: https://doi.org/10.1016/S0140-6736(15)00803-XArmstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679–690. doi: https://doi.org/10.1016/S0140-6736(15)00803-XОжирение у детей: клинические рекомендации / Российская ассоциация эндокринологов; Общество бариатрических хирургов. — М.: Минздрав России; 2024. — 79 с. Доступно по: https://cr.minzdrav.gov.ru/preview-cr/229_3. Ссылка активна на 03.04.2025.Ozhirenie u detei: Clinical guidelines. Russian Association of Endocrinologists; Society of Bariatric Surgeons. Moscow: Ministry of Health of Russia; 2024. 79 p. (In Russ). Доступно по: https://cr.minzdrav.gov.ru/preview-cr/229_3. Ссылка активна на 03.04.2025.Vos MB, Jin R, Konomi JV, et al. A randomized, controlled, crossover pilot study of losartan for pediatric nonalcoholic fatty liver disease. Pilot Feasibility Stud. 2018;4:109. doi: https://doi.org/10.1186/s40814-018-0306-4Vos MB, Jin R, Konomi JV, et al. A randomized, controlled, crossover pilot study of losartan for pediatric nonalcoholic fatty liver disease. Pilot Feasibility Stud. 2018;4:109. doi: https://doi.org/10.1186/s40814-018-0306-4Inge TH, Courcoulas AP, Jenkins TM, et al. Weight loss and health status 3 years after bariatric surgery in adolescents. N Engl J Med. 2016;374(2):113–123. doi: https://doi.org/10.1056/NEJMoa1506699Inge TH, Courcoulas AP, Jenkins TM, et al. Weight loss and health status 3 years after bariatric surgery in adolescents. N Engl J Med. 2016;374(2):113–123. doi: https://doi.org/10.1056/NEJMoa1506699Alqahtani AR, Elahmedi MO, Al Qahtani A. Co-morbidity resolution in morbidly obese children and adolescents undergoing sleeve gastrectomy. Surg Obes Relat Dis. 2014;10(5):842–850. doi: https://doi.org/10.1016/j.soard.2014.01.020Alqahtani AR, Elahmedi MO, Al Qahtani A. Co-morbidity resolution in morbidly obese children and adolescents undergoing sleeve gastrectomy. Surg Obes Relat Dis. 2014;10(5):842–850. doi: https://doi.org/10.1016/j.soard.2014.01.020Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643–654.e1–e9; quiz e39– e40. doi: https://doi.org/10.1016/j.cgh.2014.04.014Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643–654.e1–e9; quiz e39– e40. doi: https://doi.org/10.1016/j.cgh.2014.04.014Bedossa P. Current histological classification of NAFLD: strength and limitations. Hepatol Int. 2013;7(Suppl 2):765–770. doi: https://doi.org/10.1007/s12072-013-9446-zBedossa P. Current histological classification of NAFLD: strength and limitations. Hepatol Int. 2013;7(Suppl 2):765–770. doi: https://doi.org/10.1007/s12072-013-9446-zBedossa P. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014;60(2):565–575. doi: https://doi.org/10.1002/hep.27173Bedossa P. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014;60(2):565–575. doi: https://doi.org/10.1002/hep.27173

The authors declare that there are no conflicts of interest present.